FindTrial
Sign In

KOFU study A cross-sectional web survey study on biologics benefit in view of severe asthma patients

KOFU study A cross-sectional web survey study on biologics benefit in view of severe asthma patients - KOFU study A cross-sectional web survey study on biologics benefit in view of severe asthma patients

Status
Active, not recruiting
Phases
Unknown
Study type
Unknown
Source
JPRN
Registry ID
JPRN-UMIN000043238
Enrollment
700
Registered
2021-02-03
Start date
2021-02-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

asthma

Interventions

None listed

Sponsors

AstraZeneca K.K.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) Electric informed consent on the web-site 2) Females and males aged 20 years or older at time of enrollment 3) History of physician-diagnosed asthma requiring treatment at one year or more prior to enrolment 4) Be continuously treated by daily ICS or ICS/LABA to enrolment 5) Severe asthma patients treated by high dose ICS plus additional treatment, OCS or biologics

Exclusion criteria

Exclusion criteria: 1) Patients who cannot complete all questions of this survey's questionnaire 2) Patients who answered questions in less than 2 seconds per question in average

Design outcomes

Primary

MeasureTime frame
To evaluate patients satisfaction, subjective impression for asthma and patients impression for current treatment in severe asthma patients with biologics (BIO) treatment, and severe asthma patients without BIO treatment and previously recommended to use BIO treatment—

Countries

Japan

Contacts

Public ContactKensuke Fujimoto

Mebix, Inc. Devision of research promotion

fujimoto@mebix.co.jp03-4362-4500

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026